Physician profile
Ryan Scott Mandell
NPI 1598920183
$3,675.99
in general payments reported to CMS, 2019-2025
16 companies · $747 in 2025
The $747 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $99.49 · 2021: $196 · 2022: $301 · 2023: $1,304 · 2024: $522 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807 · Travel and Lodging: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.37 |
| Travel and Lodging | $765.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,214.13 | 2019-2025 | Aveir, Ensite, Gallant |
| Janssen Pharmaceuticals, INC | $305.15 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $238.08 | 2019-2025 | Lifevest |
| Cardiva Medical, INC. | $219.31 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $144.09 | 2023-2025 | Verquvo |
| Philips North America LLC | $111.58 | 2025 | Lm Undivided, Ecc Solutions |
| Novartis Pharmaceuticals Corporation | $101.19 | 2023 | |
| Astellas Pharma US INC | $64.23 | 2020-2021 | |
| Pfizer INC. | $55.86 | 2021 | |
| Altathera Pharmaceuticals LLC | $41.87 | 2023-2025 | Sotalol Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $39.14 | 2024-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $35.30 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.63 | 2019 | |
| Amgen INC. | $25.97 | 2019 | |
| Biotronik INC. | $24.61 | 2025 | Biomonitor |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $22.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mandell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.